Radiotherapy in the Era of Immunotherapy With a Focus on Non-Small-Cell Lung Cancer: Time to Revisit Ancient Dogmas?

per Khalifa, Jonathan, Mazieres, Julien, Gomez-Roca, Carlos, Ayyoub, Maha, Moyal, Elizabeth Cohen-Jonathan
Publicat a Front Oncol (2021)

Phase I dose-escalation study of F14512, a polyamine-vectorized topoisomerase II inhibitor, in patients with platinum-refractory or resistant ovarian cancer

per Leary, Alexandra, Le Tourneau, Christophe, Varga, Andrea, Sablin, Marie-Paule, Gomez-Roca, Carlos, Guilbaud, Nicolas, Petain, Aurelie, Pavlyuk, Mariya, Delord, Jean-Pierre
Publicat a Invest New Drugs (2018)

Sicca Syndrome Induced by Immune Checkpoint Inhibitor Therapy: Optimal Management Still Pending

per Ortiz Brugués, Ariadna, Sibaud, Vincent, Herbault‐Barrés, Beatrice, Betrian, Sarah, Korakis, Iphigenie, De Bataille, Caroline, Gomez‐Roca, Carlos, Epstein, Joel, Vigarios, Emmanuelle
Publicat a Oncologist (2019)

Phase I trial of afatinib and 3-weekly trastuzumab with optimal anti-diarrheal management in patients with HER2-positive metastatic cancer

per Martin, Nicolas, Isambert, Nicolas, Gomez-Roca, Carlos, Goeldner, Rainer-Georg, Zanetta, Sylvie, Sadrolhefazi, Behbood, de Mont-Serrat, Hélène, Campone, Mario, Delord, Jean-Pierre
Publicat a Cancer Chemother Pharmacol (2018)

Tumor Growth Rate (TGR) is an early indicator of anti-tumor drug activity in phase I clinical trials

per Ferté, Charles, Fernandez, Marianna, Hollebecque, Antoine, Koscielny, Serge, Levy, Antonin, Massard, Christophe, Balheda, Rastislav, Bot, Brian, Gomez-Roca, Carlos, Dromain, Clarisse, Ammari, Samy, Soria, Jean-Charles
Publicat 2013

Clinical Response of Carcinomas Harboring the BRD4-NUT Oncoprotein to the Targeted Bromodomain Inhibitor OTX015/MK-8628

per Stathis, Anastasios, Zucca, Emanuele, Bekradda, Mohamed, Gomez-Roca, Carlos, Delord, Jean-Pierre, de La Motte Rouge, Thibault, Uro-Coste, Emmanuelle, de Braud, Filippo, Pelosi, Giuseppe, French, Christopher A.
Publicat a Cancer Discov (2016)

Phase I clinical study of RG7356, an anti-CD44 humanized antibody, in patients with acute myeloid leukemia

per Vey, Norbert, Delaunay, Jacques, Martinelli, Giovanni, Fiedler, Walter, Raffoux, Emmanuel, Prebet, Thomas, Gomez-Roca, Carlos, Papayannidis, Cristina, Kebenko, Maxim, Paschka, Peter, Christen, Randolph, Guarin, Ernesto, Bröske, Ann-Marie, Baehner, Monika, Brewster, Michael, Walz, Antje-Christine, Michielin, Francesca, Runza, Valeria, Meresse, Valerie, Recher, Christian
Publicat a Oncotarget (2016)

The Activity of Crizotinib in Chemo-Refractory MET-Amplified Esophageal and Gastric Adenocarcinomas: Results from the AcSé-Crizotinib Program

per Aparicio, Thomas, Cozic, Nathalie, de la Fouchardière, Christelle, Meriaux, Emeline, Plaza, Jérome, Mineur, Laurent, Guimbaud, Rosine, Samalin, Emmanuelle, Mary, Florence, Lecomte, Thierry, Gomez-Roca, Carlos, Haineaux, Paul-Arthur, Gratet, Alain, Selves, Jannick, Menu, Yves, Colignon, Nikias, Johnson, Laetitia, Legrand, Frédéric, Vassal, Gilles
Publicat a Target Oncol (2021)

Safety and antitumor activity of the anti–PD-1 antibody pembrolizumab in patients with advanced colorectal carcinoma

per O’Neil, Bert H., Wallmark, John M., Lorente, David, Elez, Elena, Raimbourg, Judith, Gomez-Roca, Carlos, Ejadi, Samuel, Piha-Paul, Sarina A., Stein, Mark N., Abdul Razak, Albiruni R., Dotti, Katia, Santoro, Armando, Cohen, Roger B., Gould, Marlena, Saraf, Sanatan, Stein, Karen, Han, Sae-Won
Publicat a PLoS One (2017)

From presentation to paper: Gender disparities in oncological research

per Dijksterhuis, Willemieke P.M., Stroes, Charlotte I., Tan, Wan‐Ling, Ithimakin, Suthinee, Calles, Antonio, van Oijen, Martijn G.H., Verhoeven, Rob H.A., Barriuso, Jorge, Oosting, Sjoukje F., Ivankovic, Daniela Kolarevic, Furness, Andrew J.S., Bozovic‐Spasojevic, Ivana, Gomez‐Roca, Carlos, van Laarhoven, Hanneke W.M.
Publicat a Int J Cancer (2019)

A Phase 1 dose-escalation study to evaluate safety, pharmacokinetics and pharmacodynamics of AsiDNA, a first-in-class DNA repair inhibitor, administered intravenously in patients w...

per Le Tourneau, Christophe, Delord, Jean-Pierre, Kotecki, Nuria, Borcoman, Edith, Gomez-Roca, Carlos, Hescot, Ségolène, Jungels, Christiane, Vincent-Salomon, Anne, Cockenpot, Vincent, Eberst, Lauriane, Molé, Audrey, Jdey, Wael, Bono, Françoise, Trochon-Joseph, Véronique, Toussaint, Hélène, Zandanel, Christelle, Adamiec, Olga, de Beaumont, Olivier, Cassier, Philippe Alexandre
Publicat a Br J Cancer (2020)

PD-1 blockade restores helper activity of tumor-infiltrating, exhausted PD-1(hi)CD39(+) CD4 T cells

per Balança, Camille-Charlotte, Salvioni, Anna, Scarlata, Clara-Maria, Michelas, Marie, Martinez-Gomez, Carlos, Gomez-Roca, Carlos, Sarradin, Victor, Tosolini, Marie, Valle, Carine, Pont, Frédéric, Ferron, Gwénaël, Gladieff, Laurence, Vergez, Sébastien, Dupret-Bories, Agnès, Mery, Eliane, Rochaix, Philippe, Fournié, Jean-Jacques, Delord, Jean-Pierre, Devaud, Christel, Martinez, Alejandra, Ayyoub, Maha
Publicat a JCI Insight (2021)

First-in-human phase I clinical trial of RG7356, an anti-CD44 humanized antibody, in patients with advanced, CD44-expressing solid tumors

per Menke-van der Houven van Oordt, C. Willemien, Gomez-Roca, Carlos, van Herpen, Carla, Coveler, Andrew L., Mahalingam, Devalingam, Verheul, Henk M. W., van der Graaf, Winette T. A., Christen, Randolph, Rüttinger, Dominik, Weigand, Stefan, Cannarile, Michael A., Heil, Florian, Brewster, Michael, Walz, Antje-Christine, Nayak, Tapan K., Guarin, Ernesto, Meresse, Valerie, Le Tourneau, Christophe
Publicat a Oncotarget (2016)

Phase Ib study of anti-CSF-1R antibody emactuzumab in combination with CD40 agonist selicrelumab in advanced solid tumor patients

per Machiels, Jean-Pascal, Gomez-Roca, Carlos, Michot, Jean-Marie, Zamarin, Dmitriy, Mitchell, Tara, Catala, Gaetan, Eberst, Lauriane, Jacob, Wolfgang, Jegg, Anna-Maria, Cannarile, Michael A, Watson, Carl, Babitzki, Galina, Korski, Konstanty, Klaman, Irina, Teixeira, Priscila, Hoves, Sabine, Ries, Carola, Meneses-Lorente, Georgina, Michielin, Francesca, Christen, Randolph, Rüttinger, Dominik, Weisser, Martin, Delord, Jean-Pierre, Cassier, Philippe
Publicat a J Immunother Cancer (2020)

Dose-painting multicenter phase III trial in newly diagnosed glioblastoma: the SPECTRO-GLIO trial comparing arm A standard radiochemotherapy to arm B radiochemotherapy with simulta...

per Laprie, Anne, Ken, Soléakhéna, Filleron, Thomas, Lubrano, Vincent, Vieillevigne, Laure, Tensaouti, Fatima, Catalaa, Isabelle, Boetto, Sergio, Khalifa, Jonathan, Attal, Justine, Peyraga, Guillaume, Gomez-Roca, Carlos, Uro-Coste, Emmanuelle, Noel, Georges, Truc, Gilles, Sunyach, Marie-Pierre, Magné, Nicolas, Charissoux, Marie, Supiot, Stéphane, Bernier, Valérie, Mounier, Muriel, Poublanc, Muriel, Fabre, Amandine, Delord, Jean-Pierre, Cohen-Jonathan Moyal, Elizabeth
Publicat a BMC Cancer (2019)

ACTR-30. UPDATED EFFICACY AND SAFETY OF DABRAFENIB PLUS TRAMETINIB IN PATIENTS WITH RECURRENT/REFRACTORY BRAF V600E–MUTATED HIGH-GRADE GLIOMA (HGG) AND LOW-GRADE GLIOMA (LGG)

per Wen, Patrick, Stein, Alexander, van den Bent, Martin, De Greve, Jacques, Dietrich, Sascha, De Vos, Filip, von Bubnoff, Nikolas, van Linde, Myra, Lai, Albert, Prager, Gerald, Campone, Mario, Fasolo, Angelica, Lopez-Martin, Jose, Min Kim, Tae, Mason, Warren, Hofheinz, Ralf-Dieter, Blay, Jean-Yves, Cho, Daniel, Gazzah, Anas, Gomez-Roca, Carlos, Yachnin, Jeffrey, Boran, Aislyn, Burgess, Paul, Palanichamy, Ilan, Gasal, Eduard, Subbiah, Vivek
Publicat a Neuro Oncol (2019)